Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Budigalimab + SC-006 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Budigalimab | ABBV181|ABBV 181|ABBV-181 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Budigalimab is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32770720). | |
SC-006 | SC006|SC 006 | SC-006 is an antibody-drug conjugate (ADC) comprising an antibody targeted against RNF43 linked to a DNA crosslinking agent, with potential antitumor activity (Cancer Res (2020) 80 (16_Supplement): CT167). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|